DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Loupakis F. et al.
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Eur J Cancer 2014;
50: 57-63
We do not assume any responsibility for the contents of the web pages of other providers.